TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$1.46 -0.05 (-3.31%) As of 09:44 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock About Oncolytics Biotech Stock (TSE:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's RangeC$1.43▼C$1.5250-Day RangeC$0.45▼C$1.7052-Week RangeC$0.44▼C$2.08Volume13,562 shsAverage Volume139,523 shsMarket CapitalizationC$112.53 millionP/E RatioN/ADividend Yield0.31%Price TargetC$3.50Consensus RatingHold Company Overview Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Read More Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreONC MarketRank™: Oncolytics Biotech scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingOncolytics Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 12.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media2.3 / 5News Sentiment0.17 News SentimentOncolytics Biotech has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Oncolytics Biotech this week, compared to 2 articles on an average week.Search Interest13 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.82% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 1.75% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesNext-Gen Cancer Treatments Gain Steam Amid Oncology Industry ShakeupsJuly 10 at 2:58 PM | baystreet.caEquity Insider: Amid NCI Budget Fears, Emerging Oncology Stocks Gain AttentionJuly 8 at 10:51 AM | finanznachrichten.deTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 11 at 2:00 AM | Porter & Company (Ad)Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep CutsJuly 8 at 10:51 AM | baystreet.caOncolytics Biotech Inc.: Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development StrategyJune 30, 2025 | finanznachrichten.deWhy Early-Onset Cancers Are Alarming Researchers—and What It Means for InvestorsJune 30, 2025 | baystreet.caUSA News Group: The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?June 26, 2025 | finanznachrichten.deNew Wave of Cancer Treatments Could Change the Game for Patients - and InvestorsJune 24, 2025 | baystreet.caSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$1.33 at the start of the year. Since then, ONC stock has increased by 13.5% and is now trading at C$1.51. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) released its earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Company Calendar Last Earnings11/12/2024Today7/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Price Target for Oncolytics BiotechC$3.50 High Price TargetC$3.50 Low Price TargetC$3.50 Potential Upside/Downside+131.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$27.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.94% Return on Assets-71.33% Debt Debt-to-Equity Ratio11.75 Current Ratio2.99 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.36 per share Price / Cash Flow4.22 Book ValueC$0.12 per share Price / Book12.84Miscellaneous Outstanding Shares77,074,100Free FloatN/AMarket CapC$116.38 million OptionableNot Optionable Beta1.35 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (TSE:ONC) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.